Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 maintenance enzastaurin versus placebo to prevent relapse in high-risk DLBCL after R-CHOP
2005-004630-41Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL) comparing Enzastaurin maintenance with Placebo maintenance (2 arms). Primary endpoint: Overall disease-free survival. Started Feb 2006; status: terminated.
02
Drugs
enzastaurin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2005-004630-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004630-41.